Search

Your search keyword '"Dodesini, Alessandro Roberto"' showing total 28 results
Start Over Author "Dodesini, Alessandro Roberto"
28 results on '"Dodesini, Alessandro Roberto"'

2. Development of a New Model of Insulin Sensitivity in Patients With Type 2 Diabetes and Association With Mortality.

Author

Ciardullo, Stefano, Dodesini, Alessandro Roberto, Lepore, Giuseppe, Corsi, Anna, Scaranna, Cristiana, Perseghin, Gianluca, and Trevisan, Roberto

Subjects
TYPE 2 diabetes, INSULIN resistance, MORTALITY
Abstract

Context Despite being one of the major drivers of diabetes incidence, the degree of insulin resistance in patients with type 2 diabetes (T2D) is not usually evaluated in clinical practice or in large epidemiologic studies. Objective To identify a model of insulin sensitivity using widely available clinical and laboratory parameters in patients with T2D and evaluate its association with all-cause and cardiovascular mortality. Methods One hundred forty patients with T2D underwent a euglycemic hyperinsulinemic clamp to measure total body glucose disposal rate (mg kg−1 minute−1). We used demographic, clinical, and common laboratory parameters to estimate insulin sensitivity (IS) via stepwise linear regression on 85 patients (training cohort) and validated it in the remaining 55 (validation cohort). The identified equation was then applied to 3553 patients with T2D from the 1999-2010 cycles of the National Health and Nutrition Examination Survey (NHANES) to evaluate its association with all-cause and cardiovascular mortality up to December 2015. Results The best model included triglycerides, gamma glutamyl transpeptidase, albumin excretion rate, and body mass index. The identified IS score correlated well with the clamp-derived glucose disposal rate in both the training (r = 0.77, P <.001) and the validation (r = 0.74, P <.001) cohorts. In the NHANES cohort, after a median follow-up of 8.3 years, 1054 patients died, 265 of cardiovascular causes. In a multivariable Cox proportional hazard model adjusted for age, sex, race-ethnicity, education, cigarette smoke, total cholesterol, chronic kidney disease, blood pressure, prevalent cardiovascular disease, and alcohol consumption, a higher estimated IS was associated with a lower risk of both all-cause and cardiovascular mortality. Conclusion We propose a new model of IS in patients with T2D based on readily available clinical and laboratory data. Its potential applications are in both diagnosis as well as prognostication. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Advanced Hybrid Closed-Loop System Achieves and Maintains Recommended Time in Range Levels for Up To 2 Years: Predictors of Best Efficacy

Author

Lepore, Giuseppe, primary, Borella, Nicolò Diego, additional, Castagna, Giona, additional, Ippolito, Silvia, additional, Bonfadini, Silvia, additional, Corsi, Anna, additional, Scaranna, Cristiana, additional, Dodesini, Alessandro Roberto, additional, Bellante, Rosalia, additional, and Trevisan, Roberto, additional

Published
2023
Full Text
View/download PDF

13. Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study

Author

Solerte, Sebastiano Bruno, primary, D’Addio, Francesca, additional, Trevisan, Roberto, additional, Lovati, Elisabetta, additional, Rossi, Antonio, additional, Pastore, Ida, additional, Dell’Acqua, Marco, additional, Ippolito, Elio, additional, Scaranna, Cristiana, additional, Bellante, Rosalia, additional, Galliani, Silvia, additional, Dodesini, Alessandro Roberto, additional, Lepore, Giuseppe, additional, Geni, Francesca, additional, Fiorina, Roberta Maria, additional, Catena, Emanuele, additional, Corsico, Angelo, additional, Colombo, Riccardo, additional, Mirani, Marco, additional, De Riva, Carlo, additional, Oleandri, Salvatore Endrio, additional, Abdi, Reza, additional, Bonventre, Joseph V., additional, Rusconi, Stefano, additional, Folli, Franco, additional, Di Sabatino, Antonio, additional, Zuccotti, Gianvincenzo, additional, Galli, Massimo, additional, and Fiorina, Paolo, additional

Published
2020
Full Text
View/download PDF

16. Continuous subcutaneous insulin infusion reduces maternal and neonatal risk in pregnant women with type 1 diabetes: An observational cohort study of 122 pregnancies

Author

Dodesini, Alessandro Roberto, primary, Cavalli, Giorgia, additional, Ciriello, Elena, additional, Lepore, Giuseppe, additional, Corsi, Anna, additional, Scaranna, Cristiana, additional, Bellante, Rosalia, additional, Albizzi, Mascia, additional, Galliani, Silvia, additional, Mangili, Giovanna, additional, and Trevisan, Roberto, additional

Published
2020
Full Text
View/download PDF

19. Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes

Author

Valoti, Elisabetta, primary, Noris, Marina, additional, Perna, Annalisa, additional, Rurali, Erica, additional, Gherardi, Giulia, additional, Breno, Matteo, additional, Parvanova Ilieva, Aneliya, additional, Petrov Iliev, Ilian, additional, Bossi, Antonio, additional, Trevisan, Roberto, additional, Dodesini, Alessandro Roberto, additional, Ferrari, Silvia, additional, Stucchi, Nadia, additional, Benigni, Ariela, additional, Remuzzi, Giuseppe, additional, and Ruggenenti, Piero, additional

Published
2019
Full Text
View/download PDF

25. Measurable Urinary Albumin Predicts Cardiovascular Risk among Normoalbuminuric Patients with Type 2 Diabetes

Author

Ruggenenti, Piero, primary, Porrini, Esteban, additional, Motterlini, Nicola, additional, Perna, Annalisa, additional, Ilieva, Aneliya Parvanova, additional, Iliev, Ilian Petrov, additional, Dodesini, Alessandro Roberto, additional, Trevisan, Roberto, additional, Bossi, Antonio, additional, Sampietro, Giuseppe, additional, Capitoni, Enrica, additional, Gaspari, Flavio, additional, Rubis, Nadia, additional, Ene-Iordache, Bogdan, additional, and Remuzzi, Giuseppe, additional

Published
2012
Full Text
View/download PDF

26. The Hyperfiltering Kidney in Diabetes

Author

Trevisan, Roberto and Dodesini, Alessandro Roberto

Abstract

Hyperfiltering kidney is a typical feature of diabetes. Improvement observed with regard to glucose control and blood pressure control reduces the high glomerular filtration rate and may contribute to retard the appearance and the progression of diabetic renal disease. Although the mechanism of hyperfiltration is still unclear, there is mounting evidence that the increased reabsorption of glucose and sodium by sodium glucose transporter-2 (SGLT-2) is involved in this altered renal function. There is a possibility that SGLT-2 inhibition may correct hyperfiltration in diabetes, adding a new therapeutic approach to halt renal disease in patients with diabetes.

Published
2017
Full Text
View/download PDF

27. Effects of a low glycemic index high in fiber diet on blood glucose in women with gestational diabetes.

Author

Dodesini, Alessandro Roberto, Donadoni, Veronica, Ciriello, Elena, Colombo, Ottavia, Patanè, Luisa, Galliani, Silvia, Cortinovis, Fiorenzo, and Trevisan, Roberto

Subjects
*DIETARY fiber, *GLYCEMIC index, *BLOOD sugar, *GESTATIONAL diabetes, *ELEMENTAL diet, *OATS
Abstract

Diet is the first line and the main therapeutic strategy in the treatment of gestational diabetes (GDM) with the primary objective to achieve normal blood glucose levels while promoting adequate maternal weight gain and fetal growth. In the L diet, glycemic index and fiber content were <=50 and >=35 g daily, respectively, while in the M diet they were >50 and <35 g daily. Only four patients (1 in the L diet group, 3 in M diet group) have disregarded the nutritional prescription thus necessitating insulin therapy. [Extracted from the article]

Published
2021
Full Text
View/download PDF

28. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial.

Author

Ruggenenti P, Lauria G, Iliev IP, Fassi A, Ilieva AP, Rota S, Chiurchiu C, Barlovic DP, Sghirlanzoni A, Lombardi R, Penza P, Cavaletti G, Piatti ML, Frigeni B, Filipponi M, Rubis N, Noris G, Motterlini N, Ene-Iordache B, Gaspari F, Perna A, Zaletel J, Bossi A, Dodesini AR, Trevisan R, and Remuzzi G

Subjects
Adult, Aged, Angiotensin-Converting Enzyme Inhibitors administration & dosage, Angiotensin-Converting Enzyme Inhibitors adverse effects, Blood Glucose analysis, Body Mass Index, Calcium Channel Blockers administration & dosage, Calcium Channel Blockers adverse effects, Diabetes Mellitus, Type 2 diagnosis, Diabetes Mellitus, Type 2 drug therapy, Diabetic Nephropathies prevention & control, Dihydropyridines adverse effects, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Hypertension diagnosis, Hypertension mortality, Indans adverse effects, Kidney Function Tests, Male, Middle Aged, Nitrobenzenes, Piperazines, Prognosis, Risk Assessment, Severity of Illness Index, Survival Rate, Treatment Outcome, Blood Glucose drug effects, Diabetes Mellitus, Type 2 complications, Dihydropyridines administration & dosage, Hypertension complications, Hypertension drug therapy, Indans administration & dosage
Abstract

To assess whether angiotensin-converting enzyme inhibitors and third-generation dihydropyridine calcium channel blockers ameliorate diabetic complications, we compared glomerular filtration rate (GFR; primary outcome), cardiovascular events, retinopathy, and neuropathy in 380 hypertensive type 2 diabetics with albuminuria <200 mg/min included in a multicenter, double-blind, placebo-controlled trial (DEMAND [Delapril and Manidipine for Nephroprotection in Diabetes]) and randomized to 3-year treatment with manidipine/delapril combination (10/30 mg/d; n=126), delapril (30 mg/d; n=127), or placebo (n=127). GFR was centrally measured by iohexol plasma clearance. Median monthly GFR decline (interquartile range [IQR]) was 0.32 mL/min per 1.73 m(2) (IQR: 0.16-0.50 mL/min per 1.73 m(2)) on combined therapy, 0.36 mL/min per 1.73 m(2) (IQR: 0.18-0.53 mL/min per 1.73 m(2)) on delapril, and 0.30 mL/min per 1.73 m(2) (IQR: 0.12-0.50 mL/min per 1.73 m(2)) on placebo (P=0.87 and P=0.53 versus combined therapy or delapril, respectively). Similar findings were observed when baseline GFR values were not considered for slope analyses. Albuminuria was stable in the 3 treatment groups. The hazard ratio (95% CI) for major cardiovascular events between combined therapy and placebo was 0.17 (0.04-0.78; P=0.023). Among 192 subjects without retinopathy at inclusion, the hazard ratio for developing retinopathy between combined therapy and placebo was 0.27 (0.07-0.99; P=0.048). Among 200 subjects with centralized neurological evaluation, the odds ratios for peripheral neuropathy at 3 years between combined therapy or delapril and placebo were 0.45 (0.24-0.87; P=0.017) and 0.52 (0.27-0.99; P=0.048), respectively. Glucose disposal rate decreased from 5.8±2.4 to 5.3±1.9 mg/kg per min on placebo (P=0.03) but did not change on combined or delapril therapy. Treatment was well tolerated. In hypertensive type 2 diabetic patients, combined manidipine and delapril therapy failed to slow GFR decline but safely ameliorated cardiovascular disease, retinopathy, and neuropathy and stabilized insulin sensitivity.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results